Linked Life Data

3524789

Source:http://linkedlifedata.com/resource/pubmed/id/3524789

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1986-9-17
pubmed:abstractText
Twenty-three European centers participated in a randomized clinical trial (AML-5) to study the effect of androgens and immunotherapy during maintenance in adult acute myelogenous leukemia. Induction treatment consisted of Adriamycin (doxorubicin) 50 mg/m2 day 1, vincristine VCR 1 mg/m2 day 2, and cytosine arabinoside 80 mg/m2 every 12 hours by push injection days 3-9. Patients in complete remission were randomized into four groups: (1) 6-mercaptopurine 70 mg/m2 days 1-14, methotrexate 15 mg/m2 twice weekly days 15-28, and reinduction with daunorubicin 35 mg/m2 and vincristine 1 mg/m2 day 29; (2) chemotherapy as in group 1 plus stanozolol 0.15 mg/kg/day; (3) 6-thioguanine 70 mg/m2 orally on 4 consecutive days and cytosine arabinoside 80 mg/m2 subcutaneously day 5 every week; and (4) chemotherapy as in Group 3 plus irradiated blast cells treated with neuraminidase. Three hundred forty-eight patients were eligible and 295 were evaluable. The median age was 45 yrs. A complete remission was achieved in 64% of the patients, with 158 complete remissions randomized. Patients not randomized and patients receiving bone marrow transplantation (BMT) were analyzed separately. There was no difference in disease-free survival (DFS) or survival in the four maintenance arms. For patients reaching complete remission, the median DFS was 40 weeks, and median survival was 22 months with 30% surviving at 4 years. The overall survival was 18% at 4 years. There was no beneficial effect for DFS or survival by adding either immunotherapy or androgens to chemotherapy during maintenance. However, patients receiving immunotherapy seemed to have a higher rate of responses to reinduction after relapse than those in the other treatment arms.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0008-543X
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
58
pubmed:owner
NLM
pubmed:authorsComplete
N
pubmed:pagination
617-23
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:3524789-6-Mercaptopurine, pubmed-meshheading:3524789-Adolescent, pubmed-meshheading:3524789-Adult, pubmed-meshheading:3524789-Aged, pubmed-meshheading:3524789-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:3524789-Child, pubmed-meshheading:3524789-Clinical Trials as Topic, pubmed-meshheading:3524789-Combined Modality Therapy, pubmed-meshheading:3524789-Cytarabine, pubmed-meshheading:3524789-Daunorubicin, pubmed-meshheading:3524789-Doxorubicin, pubmed-meshheading:3524789-Humans, pubmed-meshheading:3524789-Immunotherapy, pubmed-meshheading:3524789-Leukemia, Myeloid, Acute, pubmed-meshheading:3524789-Methotrexate, pubmed-meshheading:3524789-Middle Aged, pubmed-meshheading:3524789-Prospective Studies, pubmed-meshheading:3524789-Random Allocation, pubmed-meshheading:3524789-Testosterone Congeners, pubmed-meshheading:3524789-Thioguanine, pubmed-meshheading:3524789-Time Factors, pubmed-meshheading:3524789-Vincristine
pubmed:year
1986
pubmed:articleTitle
A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult acute myelogenous leukemia. A Leukemia-Lymphoma Group Trial of the EORTC.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial